-

Medable Launches Agentic Accelerator Program to Help Life Sciences Companies Deploy Agentic AI Across Clinical Lifecycle

High-touch enablement helps sponsors operationalize industry-specific agents to realize value faster

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for agentic AI-powered clinical development, today announced its Agentic Accelerator Program to help life sciences companies transform clinical development with agentic AI. The program includes onboarding, integration support, governance, and change management to enable sponsors and contract research organizations to gain value from AI agents from day one.

Medable’s Agentic Accelerator Program dramatically improves time to value by providing strategic guidance and a clear path to implementation and scale.

Share

Surprisingly, only 22% of life sciences leaders have scaled AI across the enterprise and far fewer have transformed clinical development. As AI capabilities continue to evolve rapidly, companies need hands-on partners who provide both strategic guidance and a path to immediate impact and return on investment (ROI).

Medable’s Agentic Accelerator Program dramatically improves time to value by providing strategic guidance and a clear path to implementation and scale. The program supports customers with a dedicated team of AI clinical development experts and forward-deployed engineers (FDEs), ensuring that customers can move quickly on standard agentic use cases while also developing proprietary workflows and agentic solutions on the Medable platform.

"Agentic AI is the productivity leverage that bends the time/cost curve of today’s clinical trials. Customers want rapid time to value while also ensuring protection of their proprietary agentic clinical development strategy,” said Michelle Longmire, CEO and co-founder of Medable. “To achieve this, customers need a partner with industry expertise, a fit-for-purpose agentic platform, and a willingness to put skin in the game on the outcomes. Companies that want results choose Medable because it’s the fastest path to scalable agentic transformation for clinical trials.”

Now Available to All Agent Studio Customers

Medable is agentifying the clinical development lifecycle, from protocol initiation to study close-out with Medable Agent Studio – a purpose-built agentic AI platform for clinical development that enables sponsors and CROs to deploy AI agents across clinical workflows. It combines no-code agent creation, human-in-the-loop oversight, GxP-ready compliance controls, a clinical data ontology layer, built-in AI governance, and MCP (Model Context Protocol) connectors across clinical and enterprise systems to automate operational work while maintaining transparency, auditability, and regulatory alignment.

Learn more about the Medable agents and accelerator program at medable.com.

About Medable

Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Leader in eCOA by Everest Group, Medable’s platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California. Learn more at medable.com.

Contacts

Media Contact
Lisa Barbadora, Barbadora INK for Medable
+1 (610) 420-3413
lbarbadora@barbadoraink.com / media@medable.com

Medable Inc.

Details
Headquarters: Palo Alto, California
CEO: Michelle Longmire
Employees: 350
Organization: PRI

Release Versions

Contacts

Media Contact
Lisa Barbadora, Barbadora INK for Medable
+1 (610) 420-3413
lbarbadora@barbadoraink.com / media@medable.com

Social Media Profiles
More News From Medable Inc.

Medable CEO Michelle Longmire Featured as Guest Speaker with Leaders from Google and Mayo Clinic at Japan’s Largest Pharmaceutical Summit

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for agentic AI clinical development, today announced that its CEO and co-founder, Dr. Michelle Longmire, will be one of three international guest speakers at Japan’s largest pharmaceutical conference, Ubie Pharma Summit (May 13-14, 2026). Longmire will be speaking at the fifth annual event along with Justin Chen, MD, Clinical Specialist at Google for Health, and John Halamka, MD, President of Mayo Clinic Platform....

Medable Introduces AI Agent to Reduce Burden at Research Sites By Assisting Principal Investigators with Oversight of eCOA Data

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for AI-powered clinical development, today launched Agentic AI for research sites to reduce burden and assist principal investigators (PIs) in oversight and monitoring of electronic clinical outcome assessment (eCOA) data. Medable’s newest agent integrates seamlessly within its eCOA system workflows. Released just after Medable’s TMF and CRA agents, its PI Summary Agent continues the company’s rapid rollout of fun...

Medable Debuts AI Agent for Automating Trial Master File (TMF) Processes

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for AI-powered clinical development, today announced its TMF Agent, which brings artificial intelligence and automation to the labor-intensive processes required for trial document management. TMF Agent significantly improves quality and consistency while drastically reducing the manual effort in document management. It is built on Medable’s Agent Studio, the industry’s first agentic AI platform for clinical devel...
Back to Newsroom